By Josh Beckerman
Pacira BioSciences bought the remaining 81% equity stake of GQ Bio Therapeutics, adding a platform expected to help development of treatments for musculoskeletal pain.
The deal is worth about $32 million, net of working capital and other transaction adjustments, to equity holders other than Pacira. The net purchase price includes $18 million of cash paid at closing, $8 million to be paid over three years pursuant to a key employee holdback agreement and a post-closing indemnity holdback of $6 million.
Pacira expects the deal to provide near-term and long-term financial benefits with the elimination of future milestone payments.
The Tampa, Fla., company and GQ Bio already had a partnership for development of a manufacturing process for PCRX-201 and other products.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
February 27, 2025 18:56 ET (23:56 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.